 |
|
Hospitalizations With Adverse Events Caused by Digitalis Therapy Among Elderly Medicare Beneficiaries
Joan L. Warren, RN, PhD;
A. Marshall McBean, MD, MSc;
Steven L. Hass, RPh, PhD;
J. Daniel Babish, MPH
Arch Intern Med. 1994;154(13):1482-1487.
Abstract
| |
Background
Digitalis products are among the agents most frequently prescribed to the elderly, yet previous studies have not provided age-, race-, and sex-specific rates of utilization of digitalis by this population. Estimates of the rate of hospitalization with an adverse reaction from digitalis therapy have varied considerably between systems relying on passive reports and those using active surveillance.
Methods
Medicare data from 1985 through 1991 and data from the 1987 National Medical Expenditure Survey were used to determine population-based estimates of the use of digitalis in elderly beneficiaries by age group, sex, and race. Hospitalization rates with an adverse event caused by digitalis therapy were calculated for those persons estimated to be using digitalis. Medicare data were used to identify the frequency of selected comorbidities among persons with an adverse event caused by digitalis therapy as well as the frequency of clinical manifestations associated with digitalis intoxication.
Results
Over 3 million Medicare beneficiaries were estimated to be using digitalis in 1987. A total of 202011 hospitalizations with a coded adverse event caused by digitalis therapy were reported during the 7-year study period. Of persons estimated to be using digitalis, 8.53 per 1000 were hospitalized annually with an adverse event caused by digitalis therapy. Women, individuals with increasing age, and persons of black race, especially those with impaired renal function, were significantly (P<.05) more likely to experience hospitalization with an adverse event caused by digitalis therapy.
Conclusion
This information may help identify categories of elderly patients who require more frequent monitoring to prevent adverse effects of digitalis therapy. Changes in the format of the hospital bill to include more diagnoses along with increased mandatory reporting of adverse drug events will improve the sensitivity of Medicare data for surveillance of adverse drug events.
(Arch Intern Med. 1994;154:1482-1487)
Author Affiliations
From the Office of Research, Epidemiology Branch, Health Care Financing Administration, Baltimore, Md (Drs Warren and McBean and Mr Babish); and the Upjohn Co, Kalamazoo, Mich (Dr Hass).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998-2005
Moore et al.
Arch Intern Med 2007;167:1752-1759.
ABSTRACT
| FULL TEXT
Clinical benefits of low serum digoxin concentrations in heart failure
Adams et al.
J Am Coll Cardiol 2002;39:946-953.
ABSTRACT
| FULL TEXT
Inequality in Quality: Addressing Socioeconomic, Racial, and Ethnic Disparities in Health Care
Fiscella et al.
JAMA 2000;283:2579-2584.
ABSTRACT
| FULL TEXT
Time to Act on Drug Safety
Moore et al.
JAMA 1998;279:1571-1573.
FULL TEXT
|
